Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies

Autor: Patrick J. Hanley, Patricia R. M. Rocco, Rachele Ciccocioppo, Jaap Jan Boelens, Catherine M. Bollard, Vincenzo Bronte, Bruce L. Levine, Daniel J. Weiss, Maria Cancio
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Cancer Research
medicine.medical_treatment
Hemophagocytic
Passive
0302 clinical medicine
Adrenal Cortex Hormones
Immune Reconstitution Inflammatory Syndrome
Global health
Immunology and Allergy
Killer Cells
Genetics(clinical)
Viral
Hyperimmune response
Genetics (clinical)
Lymphohistiocytosis
Plasmapheresis
Cellular Therapy
Killer Cells
Natural
Cytokine release syndrome
STAT Transcription Factors
Oncology
030220 oncology & carcinogenesis
Natural
Immunotherapy
Coronavirus Infections
Cytokine Release Syndrome
CRS
HLH
Secondary Hemophagocytic Lymphohistiocytosis
medicine.medical_specialty
Immunology
Pneumonia
Viral
Context (language use)
Lymphohistiocytosis
Hemophagocytic
Article
03 medical and health sciences
Immune reconstitution inflammatory syndrome
medicine
Humans
Intensive care medicine
Cytokine release
Pandemics
Transplantation
business.industry
Interleukin-6
SARS-CoV-2
Immunization
Passive
COVID-19
IRIS
Cell Biology
Pneumonia
medicine.disease
COVID-19 Drug Treatment
Clinical trial
030104 developmental biology
Immunization
business
Interleukin-1
Zdroj: Cytotherapy
ISSN: 1477-2566
1465-3249
Popis: Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which treatments are desperately being sought. Even though most people infected experience mild to moderate respiratory symptoms and recover with supportive care, certain vulnerable hosts develop severe clinical deterioration. While several drugs are currently being investigated in clinical trials, there are currently no approved treatments or vaccines for COVID-19 and hence there is an unmet need to explore additional therapeutic options. At least three inflammatory disorders or syndromes associated with immune dysfunction have been described in the context of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics in common with COVID19 and associated therapies that could be worth testing in the context of clinical trials. Here we discuss these diseases, their management, and potential applications of these treatment in the context of COVID-19. We also discuss current cellular therapies that are being evaluated for the treatment of COVID-19 and/or its associated symptoms.
Databáze: OpenAIRE
Externí odkaz: